APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Sinusitis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Sinusitis Market Outlook and Growth Opportunities 2026

19 December 2025205 pages

Choose your research edition.

Industry ResearchAcute Sinusitis Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Sinusitis Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Acute Sinusitis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Sinusitis Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Sinusitis Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Acute Sinusitis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Sinusitis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Sinusitis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Sinusitis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Sinusitis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Sinusitis market include Bionorica, Bristol-Myers Squibb, Dr. Reddy's Laboratories, AstraZeneca, Amgen, Bayer, Fresenius Kabi, Pfizer and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Acute Sinusitis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Sinusitis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Sinusitis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acute Sinusitis market.

Acute Sinusitis Segment by Company

Bionorica

Bristol-Myers Squibb

Dr. Reddy's Laboratories

AstraZeneca

Amgen

Bayer

Fresenius Kabi

Pfizer

Eli Lilly and Company

Merck

Novartis

Johnson & Johnson

Sanofi

Sun Pharmaceutical

Teva Pharmaceutical

Abbott

Acute Sinusitis Segment by Type

Saline Nasal Spray

Nasal Corticosteroids

OTC Pain Relievers

Others

Acute Sinusitis Segment by Application

Hospital

Clinic

Acute Sinusitis Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Acute Sinusitis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acute Sinusitis key companies, revenue, market share, and recent developments.

3. To split the Acute Sinusitis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acute Sinusitis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Sinusitis significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Sinusitis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Sinusitis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Sinusitis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Sinusitis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Sinusitis industry.

Chapter 3: Detailed analysis of Acute Sinusitis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acute Sinusitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acute Sinusitis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Sinusitis Industry Trends Table 2. Acute Sinusitis Industry Drivers Table 3. Acute Sinusitis Industry Opportunities and Challenges Table 4. Acute Sinusitis Industry Restraints Table 5. Global Acute Sinusitis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Sinusitis Revenue Share by Company (2021-2026) Table 7. Global Acute Sinusitis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acute Sinusitis Key Company Manufacturing Base & Headquarters Table 9. Global Acute Sinusitis Company, Product Type & Application Table 10. Global Acute Sinusitis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acute Sinusitis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Saline Nasal Spray Table 15. Significant Companies of Nasal Corticosteroids Table 16. Significant Companies of OTC Pain Relievers Table 17. Significant Companies of Others Table 18. Global Acute Sinusitis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Acute Sinusitis Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Acute Sinusitis Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Acute Sinusitis Sales Value Share by Type (2021-2026) Table 22. Global Acute Sinusitis Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Global Acute Sinusitis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Acute Sinusitis Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Acute Sinusitis Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Acute Sinusitis Sales Value Share by Application (2021-2026) Table 29. Global Acute Sinusitis Sales Value Share by Application (2027-2032) Table 30. Global Acute Sinusitis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Acute Sinusitis Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Acute Sinusitis Sales Value Share by Region (2021-2026) Table 33. Global Acute Sinusitis Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Acute Sinusitis Sales Value Share by Region (2027-2032) Table 35. Global Acute Sinusitis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Acute Sinusitis Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Acute Sinusitis Sales Value Market Share by Country (2021-2026) Table 38. Global Acute Sinusitis Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Acute Sinusitis Sales Value Market Share by Country (2027-2032) Table 40. Bionorica Company Information Table 41. Bionorica Business Overview Table 42. Bionorica Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bionorica Acute Sinusitis Product Portfolio Table 44. Bionorica Recent Development Table 45. Bristol-Myers Squibb Company Information Table 46. Bristol-Myers Squibb Business Overview Table 47. Bristol-Myers Squibb Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Bristol-Myers Squibb Acute Sinusitis Product Portfolio Table 49. Bristol-Myers Squibb Recent Development Table 50. Dr. Reddy's Laboratories Company Information Table 51. Dr. Reddy's Laboratories Business Overview Table 52. Dr. Reddy's Laboratories Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Dr. Reddy's Laboratories Acute Sinusitis Product Portfolio Table 54. Dr. Reddy's Laboratories Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. AstraZeneca Acute Sinusitis Product Portfolio Table 59. AstraZeneca Recent Development Table 60. Amgen Company Information Table 61. Amgen Business Overview Table 62. Amgen Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Amgen Acute Sinusitis Product Portfolio Table 64. Amgen Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Acute Sinusitis Product Portfolio Table 69. Bayer Recent Development Table 70. Fresenius Kabi Company Information Table 71. Fresenius Kabi Business Overview Table 72. Fresenius Kabi Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Fresenius Kabi Acute Sinusitis Product Portfolio Table 74. Fresenius Kabi Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Acute Sinusitis Product Portfolio Table 79. Pfizer Recent Development Table 80. Eli Lilly and Company Company Information Table 81. Eli Lilly and Company Business Overview Table 82. Eli Lilly and Company Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eli Lilly and Company Acute Sinusitis Product Portfolio Table 84. Eli Lilly and Company Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Acute Sinusitis Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Merck Acute Sinusitis Product Portfolio Table 89. Merck Recent Development Table 90. Novartis Company Information Table 91. Novartis Business Overview Table 92. Novartis Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Novartis Acute Sinusitis Product Portfolio Table 94. Novartis Recent Development Table 95. Johnson & Johnson Company Information Table 96. Johnson & Johnson Business Overview Table 97. Johnson & Johnson Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Johnson & Johnson Acute Sinusitis Product Portfolio Table 99. Johnson & Johnson Recent Development Table 100. Sanofi Company Information Table 101. Sanofi Business Overview Table 102. Sanofi Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sanofi Acute Sinusitis Product Portfolio Table 104. Sanofi Recent Development Table 105. Sun Pharmaceutical Company Information Table 106. Sun Pharmaceutical Business Overview Table 107. Sun Pharmaceutical Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sun Pharmaceutical Acute Sinusitis Product Portfolio Table 109. Sun Pharmaceutical Recent Development Table 110. Teva Pharmaceutical Company Information Table 111. Teva Pharmaceutical Business Overview Table 112. Teva Pharmaceutical Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Teva Pharmaceutical Acute Sinusitis Product Portfolio Table 114. Teva Pharmaceutical Recent Development Table 115. Abbott Company Information Table 116. Abbott Business Overview Table 117. Abbott Acute Sinusitis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Abbott Acute Sinusitis Product Portfolio Table 119. Abbott Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Acute Sinusitis Product Image Figure 2. Global Acute Sinusitis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Sinusitis Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Sinusitis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Saline Nasal Spray Image Figure 8. Nasal Corticosteroids Image Figure 9. OTC Pain Relievers Image Figure 10. Others Image Figure 11. Global Acute Sinusitis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Acute Sinusitis Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Acute Sinusitis Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Global Acute Sinusitis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Acute Sinusitis Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Acute Sinusitis Sales Value Share by Application (2021-2032) Figure 19. Global Acute Sinusitis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Acute Sinusitis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Acute Sinusitis Sales Value (2021-2032) & (US$ Million) Figure 22. North America Acute Sinusitis Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Acute Sinusitis Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Acute Sinusitis Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Acute Sinusitis Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Acute Sinusitis Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Acute Sinusitis Sales Value (2021-2032) & (US$ Million) Figure 28. South America Acute Sinusitis Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Acute Sinusitis Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Acute Sinusitis Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Acute Sinusitis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Acute Sinusitis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Acute Sinusitis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Saline Nasal Spray
  • Nasal Corticosteroids
  • OTC Pain Relievers
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • Bionorica
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories
  • AstraZeneca
  • Amgen
  • Bayer
  • Fresenius Kabi
  • Pfizer
  • Eli Lilly and Company
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Sinusitis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Sinusitis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acute Sinusitis Market Dynamics
  1. 2.1 Acute Sinusitis Industry Trends
  2. 2.2 Acute Sinusitis Industry Drivers
  3. 2.3 Acute Sinusitis Industry Opportunities and Challenges
  4. 2.4 Acute Sinusitis Industry Restraints
3 Acute Sinusitis Market by Company
  1. 3.1 Global Acute Sinusitis Company Revenue Ranking in 2025
  2. 3.2 Global Acute Sinusitis Revenue by Company (2021-2026)
  3. 3.3 Global Acute Sinusitis Company Ranking (2024-2026)
  4. 3.4 Global Acute Sinusitis Company Manufacturing Base and Headquarters
  5. 3.5 Global Acute Sinusitis Company Product Type and Application
  6. 3.6 Global Acute Sinusitis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acute Sinusitis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acute Sinusitis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acute Sinusitis Market by Type
  1. 4.1 Acute Sinusitis Type Introduction
  2. 4.1.1 Saline Nasal Spray
  3. 4.1.2 Nasal Corticosteroids
  4. 4.1.3 OTC Pain Relievers
  5. 4.1.4 Others
  6. 4.2 Global Acute Sinusitis Sales Value by Type
  7. 4.2.1 Global Acute Sinusitis Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Acute Sinusitis Sales Value by Type (2021-2032)
  9. 4.2.3 Global Acute Sinusitis Sales Value Share by Type (2021-2032)
5 Acute Sinusitis Market by Application
  1. 5.1 Acute Sinusitis Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Acute Sinusitis Sales Value by Application
  5. 5.2.1 Global Acute Sinusitis Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Acute Sinusitis Sales Value by Application (2021-2032)
  7. 5.2.3 Global Acute Sinusitis Sales Value Share by Application (2021-2032)
6 Acute Sinusitis Regional Value Analysis
  1. 6.1 Global Acute Sinusitis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Sinusitis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acute Sinusitis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acute Sinusitis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Sinusitis Sales Value (2021-2032)
  7. 6.3.2 North America Acute Sinusitis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acute Sinusitis Sales Value (2021-2032)
  10. 6.4.2 Europe Acute Sinusitis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acute Sinusitis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acute Sinusitis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acute Sinusitis Sales Value (2021-2032)
  16. 6.6.2 South America Acute Sinusitis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acute Sinusitis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acute Sinusitis Sales Value Share by Country, 2025 VS 2032
7 Acute Sinusitis Country-level Value Analysis
  1. 7.1 Global Acute Sinusitis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Sinusitis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acute Sinusitis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acute Sinusitis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acute Sinusitis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acute Sinusitis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acute Sinusitis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acute Sinusitis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acute Sinusitis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acute Sinusitis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acute Sinusitis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acute Sinusitis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acute Sinusitis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acute Sinusitis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acute Sinusitis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acute Sinusitis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acute Sinusitis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acute Sinusitis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acute Sinusitis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acute Sinusitis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acute Sinusitis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acute Sinusitis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acute Sinusitis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acute Sinusitis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acute Sinusitis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acute Sinusitis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acute Sinusitis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acute Sinusitis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acute Sinusitis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acute Sinusitis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acute Sinusitis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acute Sinusitis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acute Sinusitis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acute Sinusitis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bionorica
  2. 8.1.1 Bionorica Company Information
  3. 8.1.2 Bionorica Business Overview
  4. 8.1.3 Bionorica Acute Sinusitis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bionorica Acute Sinusitis Product Portfolio
  6. 8.1.5 Bionorica Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Acute Sinusitis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Acute Sinusitis Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Dr. Reddy's Laboratories
  14. 8.3.1 Dr. Reddy's Laboratories Company Information
  15. 8.3.2 Dr. Reddy's Laboratories Business Overview
  16. 8.3.3 Dr. Reddy's Laboratories Acute Sinusitis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Dr. Reddy's Laboratories Acute Sinusitis Product Portfolio
  18. 8.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Acute Sinusitis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Acute Sinusitis Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Acute Sinusitis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Acute Sinusitis Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Acute Sinusitis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Acute Sinusitis Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Acute Sinusitis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Acute Sinusitis Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Acute Sinusitis Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Acute Sinusitis Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Eli Lilly and Company
  50. 8.9.1 Eli Lilly and Company Company Information
  51. 8.9.2 Eli Lilly and Company Business Overview
  52. 8.9.3 Eli Lilly and Company Acute Sinusitis Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly and Company Acute Sinusitis Product Portfolio
  54. 8.9.5 Eli Lilly and Company Recent Developments
  55. 8.10 Merck
  56. 8.10.1 Merck Company Information
  57. 8.10.2 Merck Business Overview
  58. 8.10.3 Merck Acute Sinusitis Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck Acute Sinusitis Product Portfolio
  60. 8.10.5 Merck Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Acute Sinusitis Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Acute Sinusitis Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Johnson & Johnson
  68. 8.12.1 Johnson & Johnson Company Information
  69. 8.12.2 Johnson & Johnson Business Overview
  70. 8.12.3 Johnson & Johnson Acute Sinusitis Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson & Johnson Acute Sinusitis Product Portfolio
  72. 8.12.5 Johnson & Johnson Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Acute Sinusitis Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Acute Sinusitis Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Sun Pharmaceutical
  80. 8.14.1 Sun Pharmaceutical Company Information
  81. 8.14.2 Sun Pharmaceutical Business Overview
  82. 8.14.3 Sun Pharmaceutical Acute Sinusitis Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sun Pharmaceutical Acute Sinusitis Product Portfolio
  84. 8.14.5 Sun Pharmaceutical Recent Developments
  85. 8.15 Teva Pharmaceutical
  86. 8.15.1 Teva Pharmaceutical Company Information
  87. 8.15.2 Teva Pharmaceutical Business Overview
  88. 8.15.3 Teva Pharmaceutical Acute Sinusitis Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Teva Pharmaceutical Acute Sinusitis Product Portfolio
  90. 8.15.5 Teva Pharmaceutical Recent Developments
  91. 8.16 Abbott
  92. 8.16.1 Abbott Company Information
  93. 8.16.2 Abbott Business Overview
  94. 8.16.3 Abbott Acute Sinusitis Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Acute Sinusitis Product Portfolio
  96. 8.16.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst